New cocktail aims to tackle stomach cancer when first treatment fails
NCT ID NCT05585580
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (serplulimab, lenvatinib, and paclitaxel) in 59 adults with advanced stomach or gastroesophageal junction cancer that progressed after initial immunotherapy. The goal is to see if this mix can shrink tumors and extend life. Participants must have certain markers or have responded well to prior treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linyi Cancer Hospital
Linyi, China
-
Qilu hospital of Shandong univertisy
Jinan, Shandong, 250012, China
-
Qingdao Municipal Hospital（Group）
Qingdao, Shandong, 266011, China
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250012, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, 250012, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.